Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1604 Plus Chemotherapy in Advanced Cervical Cancer
NCT04864782Phase 3Terminated
- Sponsor
- Qilu Pharmaceutical
- Start
- Sep 2020
- Primary completion
- Sep 2022
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 3 trial of iparomlimab in Cervical Cancer (CC), sponsored by Qilu Pharmaceutical. Started Sep 2020; status: terminated.
02
Drugs
iparomlimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT04864782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04864782.